Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

FDA approval of Tysabri, for the treatment of multiple sclerosis

Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

24 Nov 2004

Vaccinex and Biocon to co-develop at least four therapeutic antibody products

The collaboration combines Vaccinex's unique capabilities to discover fully human monoclonal antibodies using its proprietary antibody discovery technology and Biocon's proven expertise in clinical research and biologics manufacturing.

19 Nov 2004

Abbott's investigational anti-interleukin-12 fully human monoclonal antibody in Crohn's disease study

Results of a Phase II study of Abbott's ABT-874, a fully human anti-interleukin-12 (IL-12) monoclonal antibody, will appear tomorrow in the New England Journal of Medicine citing treatment with ABT-874 shows differences in response and remission in patients with active Crohn's disease compared to placebo, in one arm of the study.

10 Nov 2004

Analysis shows Remicade reduces pain associated with Crohn's disease

According to a new sub-analysis from the ACCENT I (A Crohn's disease Clinical trial Evaluating infliximab in a New long-term Treatment regimen) trial patients who received a three-dose induction regimen of Remicade experienced a significantly greater reduction in pain as assessed by four different pain questions after ten weeks, compared with patients who received a single dose of Remicade.

2 Nov 2004

Radiotherapy with cetuximab significantly improves disease control and survival in head and neck cancer

Combination treatment using the monoclonal antibody cetuximab, along with high dose radiotherapy in the treatment of patients with loco-regionally advanced squamous cell carcinoma of the head and neck results in significant improvements in both loco-regional control and overall survival, according to Dr Jordi Giralt of Val d'Hebron University Hospital.

26 Oct 2004

Acne-like rash linked to effectiveness of new targeted cancer treatment – cetuximab

Acne is not a condition that anyone would welcome under normal circumstances, but an international study of a new targeted cancer treatment – cetuximab – has shown that patients who developed an acne-like rash responded better to the treatment than those who did not.

30 Sep 2004

New combination of drugs results in fewer incidences of rejection in liver transplant patients

“The big advantage [of this combination of drugs] is that the incidence of rejection is significantly decreased,” he says. “These results could change the standard of care for liver transplant recipients.”

23 Sep 2004

Elan and Wyeth receive patents for Alzheimer's disease treatments

Elan Corporation and Wyeth Pharmaceuticals have announced that the United States Patent and Trademark Office recently issued Neuralab Limited, a subsidiary of Elan, seven patents for the companies’ joint research on immunotherapeutic approaches to the prevention and treatment of Alzheimer’s disease.

23 Sep 2004

Mighty mouse helps researchers tackle osteoporosis

A genetically engineered 'mighty mouse' is helping Medical College of Georgia researchers find the best way for young people to build bone and avoid osteoporosis.

16 Sep 2004

Phase I clinical trial of new drug for severe asthma

Cambridge Antibody Technology today announced that it is starting a Phase I clinical trial of CAT-354, a human anti-IL-13 monoclonal antibody, which is a potential treatment for severe asthma, following recent approval from the Medicines and Healthcare products Regulatory Agency (MHRA).

8 Sep 2004

More women are surviving advanced breast cancer

Writing in the Journal of Clinical Oncology, (Vol. 22, No. 16: 3302-3308), doctors from 3 French hospitals reported on 724 women whose first diagnosis was breast cancer that had spread to other parts of the body (stage 4). It is rare for women to be diagnosed with such late stage disease.

27 Aug 2004

Phase 1 clinical trial of new anticancer drug from Human Genome Sciences

Human Genome Sciences has begun dosing patients in a Phase 1 clinical trial of HGS-TR2J, a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.

25 Aug 2004

Signet Laboratories has announced the release of ACUITY mouse-on-mouse polymer detection system

Signet's ACUITY(TM) Mouse-on-Mouse Polymer Detection System is a sensitive biotin-free detection system for use with monoclonal and polyclonal antibodies on mouse or rat tissue. ACUITY(TM) Mouse-on-Mouse provides cost savings by enabling researchers to use less antibody, while increasing staining intensity and eliminating background.

9 Aug 2004

New glycan arrays discover autoimmunogenic activities of SARS-CoV

Researchers in New York City and Guangzhou, China applied the rapidly-developing carbohydrate microarray technology to study an inactivated SARS-coronavirus (SARS-CoV) vaccine and discovered autoimmunogenic activity of this newly identified human viral pathogen.

2 Aug 2004

Women with a history of cancer in their family are better off having MRI scans instead of mammograms

New research by Mieke Kriege at the Department of Medical Oncology, Rotterdam Family Cancer Clinic suggests that women with a history of cancer in their family are better off having MRI scans instead of mammogram's.

28 Jul 2004

Several key findings from clinical trial of an investigational Alzheimer's disease treatment

Elan Corporation and Wyeth Pharmaceuticals have announced several key findings from their Phase IIa clinical trial of an investigational Alzheimer's disease (AD) treatment, AN-1792, which were presented in Philadelphia at the 9th International Conference on Alzheimer's Disease and Related Disorders.

22 Jul 2004

Erbitux (cetuximab) combined with irinotecan offers another option for patients who have colorectal cancer

Erbitux (cetuximab), offers another option for patients who have colorectal cancer that resists standard chemotherapy treatment, according to an article written by two Mayo Clinic cancer researchers published in the current edition of the New England Journal of Medicine.

21 Jul 2004

Monoclonal Antibody News and Research

Further Reading

FDA approval of Tysabri, for the treatment of multiple sclerosis

Vaccinex and Biocon to co-develop at least four therapeutic antibody products

Abbott's investigational anti-interleukin-12 fully human monoclonal antibody in Crohn's disease study

Analysis shows Remicade reduces pain associated with Crohn's disease

Radiotherapy with cetuximab significantly improves disease control and survival in head and neck cancer

Acne-like rash linked to effectiveness of new targeted cancer treatment – cetuximab

New combination of drugs results in fewer incidences of rejection in liver transplant patients

Elan and Wyeth receive patents for Alzheimer's disease treatments

Mighty mouse helps researchers tackle osteoporosis

Phase I clinical trial of new drug for severe asthma

More women are surviving advanced breast cancer

Phase 1 clinical trial of new anticancer drug from Human Genome Sciences

Signet Laboratories has announced the release of ACUITY mouse-on-mouse polymer detection system

New glycan arrays discover autoimmunogenic activities of SARS-CoV

Women with a history of cancer in their family are better off having MRI scans instead of mammograms

Several key findings from clinical trial of an investigational Alzheimer's disease treatment

Erbitux (cetuximab) combined with irinotecan offers another option for patients who have colorectal cancer

Strategic analysis of the breast cancer therapeutics pipeline

New imaging agent will enable doctors to rapidly and accurately detect those hard-to-diagnose appendicitis cases

Oxford Therapeutic Antibody Centre receives Manufacturer’s Authorisation

Monoclonal Antibody Manufacturing Trends eBook eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News